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Background: Severe viral infections are frequent and remain one of the most important cause of non-relapse mortality and morbidity in recipients of ab T cell-depleted grafts. In this analysis we have tested the hypothesis that adoptive transfer of low doses of memory T-cells is a safe way to improve immune response to common pathogens.
Methods: Fifty-one patients with non-malignant disorders received 1st ab T cell-depleted HSCT, median age was 5y(1-22), m:f-38:13. Donors were haploidentical (n-17) or matched unrelated (n-34). Only CMV seropositive donor/recipient pairs were eligible. Infusions of memory T-cells were planned at escalating doses (25 × 10 3 /kg, 50 × 10 3 /kg, 100 × 10 3 /kg in haploidentical, and 100 × 10 3 /kg, 200 × 10 3 /kg, 300 × 10 3 /kg, in MUD transplants), with monthly intervals. At the moment of 1st DLI all patients had stable graft function, no signs of active GVHD or severe infection. Memory T-cells were derived from G-CSF stimulated (n-37) or unstimulated (n-14) apheresis of the original donors. Apheresis product was processed with single-step CD45RA depletion procedure on CliniMACS Plus or Prodigy platform. CD45RA-depleted fraction was aliquoted and cryopreserved for further use. Beyond routine monitoring of CMV, EBV and Adenovirus DNA load, lymphocyte subset regeneration and hematopoietic chimerism, development of pathogenspecific (CMV, EBV, Adeno) immunity was monitored by the ELISPOT assay for IFN-gamma production in response to respective antigen stimulation.
Results: Between 26.09.14 and 18.04.2017, 51 patients received 131 memory T-cell infusions. The procedure of CD45RA depletion was effective with >4,5 log depletion of CD45RA. Final product contained negligible numbers of CD45RA+ naive T-cells. Median day of the first infusion was +35 (20-70). Eight patients (35%) had first CMV viremia before DLI#1. Seven patients developed signs of acute GVHD grade ³ II and 5 -chronic GVHD after infusion. In a group of 47 patients without prior GVHD, СI of GVHD at +1,8 year FU was 9% (7-10). Acute GVHD was grade II in all cases with involvement of skin (n = 2) or gut (n = 2) or gut + skin (n = 1). Two patients responded to the first line therapy, in 3 mild chronic GVHD developed. One patient required IST at last follow-up. In a group of 51 patients CI of TRM was 4% (1-15). Causes of death included generalized CMV infection (n = 1) and multiorgan failure + generalized CMV+ ADV infection in a patient who had received massive immunosuppressive therapy for immune hemolysis. According to ELISPOT analysis, among patients with absent CMV-specific immune reactivity at baseline (n = 34) expansion of CMV-specific T-cells was demonstrated in 16 (47%) within 100 days.
Conclusions: This preliminary analysis suggests that transfusions of low-dose memory T-cells after engraftment in non-malignant recipients of ab T cell-depleted haploidentical and unrelated HSCT are safe and potentially may provide necessary antiviral reactivity. Prospective randomized trial is warranted to determine the clinical value of this approach.
Disclosure: Nothing to declare O008 Cell-mediated immunogenicity of the adjuvanted recombinant zoster vaccine (RZV) in adult autologous hematopoietic stem cell transplant recipients: a phase 3, [EBMT 2018, abstract #O111] . T-cell immunity is considered the main mechanism of protection against HZ. Here, we report the varicella zoster vaccine glycoprotein E (gE)-specific cell-mediated immune (CMI) responses and polyfunctionality of CD4+ T cells induced by RZV in this population.
Methods: In this phase 3, observer-blind, multicenter study (NCT01610414), adults ≥18 YOA randomized 1:1 received 2 doses of RZV or placebo 1-2 months (M) apart, with the first dose given 50-70 days after autologous HSCT. CMI responses were assessed in a sub-cohort of study participants (according-to-protocol [ATP] cohort for CMI). Peripheral blood mononuclear cells were stimulated with a pool of overlapping peptides covering the entire sequence of gE antigen and the CD4+ T-cell activation markers interferon-γ, tumor necrosis factor-α, interleukin-2, and CD40 ligand were labelled by intracellular staining and analyzed by cytofluorometry. The main assessment of CMI was based on the frequency of gE-specific CD4+ T cells expressing ≥2 of these activation markers (CD4[2+] T cells) per 10^6 T cells. Polyfunctionality was analyzed post-hoc by summarizing the median frequencies of CD4+ T cells expressing 1, 2, 3, or 4 markers. Immune responses were assessed at baseline, 1M post-each dose, 12M, and 24M post-dose 2.
Results: Of the 1846 vaccinated participants, 141 (RZV: 71 and placebo: 70) were included in the CMI sub-cohort and 114 (59 and 55, respectively) in the ATP cohort for CMI. In the RZV group, frequency of CD4[2+] T cells was higher at all post-vaccination time points compared to baseline (Figure, Panel A) . Vaccine response rate was 92.9% at 1M post-dose 2 and remained above 70% at subsequent time points. The proportion of CD4+ T cells expressing 4 activation markers increased from baseline up to 24M post-dose 2, while the proportion of CD4+ T cells were 78% (95% CI, 62-88) and 69.5% (95% CI, 52-82), respectively. In univariate analysis, prior use of CPI had no effect on either acute or chronic GVHD. The 6-month grade 2-4 aGVHD CI was 39% (95% CI, 21-57) in the CPI group and 25% (95% CI, 10-44) in the non-CPI group (p = 0.23), while the 2-year CI of moderate to severe cGVHD was 16% (95% CI, 3-39) and 9% (95% CI, 1-26), respectively (p = 0.67). The 2-year CI of relapse in the CPI group was only 4% (95% CI, 0-16) versus 22% (95% CI, 8-41) (p = 0.08) in the non-CPI group. A significantly higher 2-year PFS was observed in the CPI group (89% (95% CI, 70-96) vs 54% (95% CI, 31-72), p = 0.029). No differences were observed in OS and NRM between the two cohorts, the 2-year OS was 88% (95% CI, 66-96) in the CPI group vs 71% in the non-CPI group (95% CI, 47-86) (p = 0.30), and the 2-year CI of NRM was 11% (95% CI, 4-27) vs 24% (95% CI, 8-44) (p = 0.26) respectively.
Based on the other pre-transplant characteristics, only a correlation between disease status at SCT and OS was found: the 2-year OS was 84% (95% CI, 61-94) in CR patients, 73% (95% CI, 35-91) in PR patients and 50% (95% CI, 6-85) in PD/SD patients (p = 0.04).
In multivariate analysis, disease status other than CR had a negative impact on OS (hazard ratio (HR) 6.18 (95% Cl, 1.13-33, 72) for PR and HR 14 (95% CI, 199-98.29) for PD/SD). Checkpoint inhibitors before SCT were independent protective factors for PFS (HR 0.23 (95% CI, 0.05-0.92)).
Conclusions: CPI as a bridge to haplo-SCT significantly improve the PFS in relapse/refractory HL, lowering the relapse rate. Pre-treatment with CPI did not enhance the toxicity. However, the main limitation of our study lies in the small number of patients; further studies are warranted to extend our findings. 
